Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.44% to 34,628.69 while the NASDAQ fell 1.34% to 15,571.16. The S&P also fell, dropping 1.36% to 4,592.03.
After Denying Data Leak, Olema Shares First Data For Lead Program In Breast Cancer Patients
Olema Pharmaceuticals Inc (NASDAQ: OLMA) had been preparing to present the first clinical data from its lead program in development for metastatic breast cancer at a
Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump
Midway through trading Tuesday, the Dow traded down 0.88% to 34,827.81 while the NASDAQ fell 0.78% to 15,659.31. The S&P also fell, dropping 0.3832% to 4,616.53.
Olema Oncology Issues Statement Regarding Falsified Information Circulating On Social Media
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for
48 Biggest Movers From Yesterday
Gainers
Xiaobai Maimai Inc. (NASDAQ: HX) shares surged 98.4% to settle at $18.87 on Wednesday on above-average volume. The company on Tuesday disclosed the resignation of its CEO and Chairman and announced the appointment of Yilin Wang as CEO.
Olema Oncology To Present Data On OP-1250 At 2021 JCA-AACR Precision Cancer Medicine International Conference
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for
Olema Pharmaceuticals Q2 EPS $(0.42) Up From $(0.95) YoY
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.42) per share. This is a 55.79 percent increase over losses of $(0.95) per share from the same period last year.